🟢 Stereotaxis is trading 7.5% up in pre-market with no company-specific catalyst identified

Stereotaxis is trading 7.5% up at $1.29, with no confirmed direct catalyst for the October 2 pre-market gain.

• The price compares with the October 1 close of $1.20. U.S. futures and major indices were higher pre-market, a possible backdrop but not an established cause.
• No fresh company-specific announcement explaining the move appeared in current listings; the latest prominent news concerned a planned technology showcase at HRX 2026. Healthcare was weaker, and trading-volume data was unavailable.